Tri Locum Partners LP Neurocrine Biosciences Inc Transaction History

Tri Locum Partners LP

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$92.03 - $107.81 $18.1 Million - $21.2 Million	196,390 New	196,390 $20.9 Million
Q1 2021 May 17, 2021	SELL	$87.57 - $119.4 $628,577 - $857,053	-7,178 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$86.91 - $108.33 $623,839 - $777,592	7,178 New	7,178 $688,000

624

94.2M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $11.8B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Tri Locum Partners LP, based on Form 13F filings with the SEC.

Stay updated on Tri Locum Partners LP with notifications on news.